All In Biotech

Drug Trial Radar · NCT07530666

Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia

Phase I/II Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of DS010 in Patients With Cancer Cachexia

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Oct 30, 2027

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Dartsbio Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Apr 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia

Conditions

  • Cancer
  • Cachexia

Interventions

  • DS010 injectionDrug

    Once every 3 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks or once every 4 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks or once every 4 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks or once every 4 weeks intravenously injection

  • DS010 injectionDrug

    Once every 3 weeks or once every 4 weeks intravenously injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Dose-limiting toxicity (DLT)Time frame: 21 days after the first dose
  2. Phase 1: Incidence of adverse events as assessed by CTCAE V6.0Time frame: Up to 20 weeks
  3. Phase 2: Change in body weight from baseline to Week 12Time frame: Baseline, Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.